[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sst2-positive-neuroendocrine-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sst2-positive-neuroendocrine-neoplasms":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100602879",false,"NCT07129252","A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","A Phase 1\u002F2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors","BRAVESST2","Inclusion Criteria:\n\n* Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression.\n* Have one or more measurable disease location per RECIST version 1.1.\n* Have a tumor that expresses SSR confirmed by SSR imaging.\n* Have an ECOG performance status of 0, 1, or 2.\n\nExclusion Criteria:\n\n* Have tumor progression while undergoing a course of PRRT or within 6 months of completing PRRT.\n* Have brain metastases unless asymptomatic and stable for at least one month for participants with SCLC or LCLC or at least 3 months for participants with other non-NET solid tumors.\n* Use of anticancer agents within specified intervals prior to the first dose of study drug.\n* Had surgery, chemoembolization, or radiofrequency ablation within 90 days prior to first dose of study drug.\n* Prior participation in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.\n* Participants with carcinoid syndrome.\n* Secondary malignancy: participants who have any other malignancy known to be active or treated within 3 years of the start of screening, with the exception of treated cervical intraepithelial neoplasia, superficial (noninvasive) bladder cancer, and non-melanoma skin cancer.\n* Have prior treatment with MMAE.\n* Have hypersensitivity or history of anaphylactic reaction to octreotide, other SSAs, and\u002For MMAE.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This Phase 1\u002F2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.",[27,28,29],"SST2-positive Neuroendocrine Neoplasms","Neuroendocrine Tumors","Neuroendocrine Neoplasm",[31,32,29,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48],"CRN09682","Crinetics","NEN","Neuroendocrine Tumor","NET","MMAE","SST2","Somatostatin","Metastatic","Solid Tumor","Dose Escalation","Dose Expansion","Phase 1","SSTR+","Phase 2","Phase 1\u002F2","Neuroendocrine Carcinoma","NEC","RECRUITING","2026-06-30",{"date":52,"type":53},"2026-07-01","ACTUAL",{"date":55,"type":53},"2025-11-26",{"date":57,"type":20},"2029-08",{"name":59,"class":60},"Crinetics Pharmaceuticals Inc.","INDUSTRY",26,""]